Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

Eli Lilly (NYSE:LLY) announced that its financial results for Q1 2025, prepared under the U.S. generally accepted accounting ...

Eli Lilly’s stock took a 4.6% dive after Morgan Stanley gently tapped the brakes on its optimism, lowering its price target ...

Eli Lilly shares stumbled 4.2% mid-Wednesday after Morgan Stanley clipped its price target, dropping investor spirits faster ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

The pharmaceutical and healthcare sectors were previously viewed as a relative safe haven from the tariff-induced market turmoil. The Health Care Select Sector SPDR exchange-traded fund XLV fell 7.8% ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report).

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s ...